1. Scrip
  2. >>Therapy Areas

Waksal's Kadmon rapidly builds on hepatitis C franchise with Valeant deals

 
• By Sukaina Virji

Kadmon Pharmaceuticals, Samuel Waksal's new venture, is moving quickly to strengthen its hepatitis C franchise.

Kadmon Pharmaceuticals, Samuel Waksal's new venture, is moving quickly to strengthen its hepatitis C franchise.

Having acquired a fully-formed commercial base with the acquisition of Three Rivers Pharmaceuticals recently, it has now signed two strategic agreements with Valeant Pharmaceuticals for the development and commercialisation of taribavirin and the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.